C. Jørgensen

Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer

P. Bendahl, Kristina Aaltonen, L. Rydén, 2020, Scientific Reports.

Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression

M. Fernö, K. Lövgren, P. Bendahl, 2020, Breast Cancer Research and Treatment.

The Distribution of Circulating Tumor Cells Is Different in Metastatic Lobular Compared to Ductal Carcinoma of the Breast—Long-Term Prognostic Significance

M. Fernö, P. Bendahl, Kristina Aaltonen, 2020, Cells.

PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients

T. Nielsen, B. Wallden, Shuzhen Liu, 2014, Acta oncologica.

TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group

N. Brünner, E. Balslev, B. Ejlertsen, 2014, BMC Cancer.

Universitet TIMP-1 and responsiveness to gemcitabine in advanced breast cancer

N. Brünner, E. Balslev, B. Ejlertsen, 2014 .

High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial

T. Nielsen, E. Balslev, M. Jensen, 2016, Clinical Cancer Research.

PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications

P. Bendahl, Kristina Aaltonen, L. Rydén, 2021, Cancers.

Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.

M. Andersson, S. Møller, E. Jakobsen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer

P. Bendahl, Kristina Aaltonen, L. Rydén, 2020, Scientific Reports.

TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group

N. Brünner, E. Balslev, B. Ejlertsen, 2014, BMC Cancer.